All stock lists
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
US · Delayed Price · Currency is USD
3.70+0.12 (+3.35%)
Insider Score
––Not scored
RXRX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
RXRX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 7.67 M | 6.47 M | 35.54 M | 5.17 M | 19.10 M | 14.74 M |
| Revenue Growth (YoY) | -59.85 % | -56.11 % | 687.81 % | -80.16 % | 32.62 % | 9.30 % |
| Cost of Revenue | 11.49 M | 12.49 M | 26.88 M | 29.59 M | 20.16 M | 21.83 M |
| Gross Profit | -3.82 M | -6.02 M | 8.66 M | -24.42 M | -1.06 M | -7.08 M |
| SG&A Expense | 41.53 M | 34.59 M | 33.66 M | 41.63 M | 46.65 M | 54.65 M |
| R&D Expense | 89.61 M | 87.90 M | 83.34 M | 121.06 M | 128.64 M | 129.63 M |
| Operating Expenses | 131.15 M | 122.49 M | 117.00 M | 147.78 M | 175.17 M | 184.28 M |
| Operating Income | -134.97 M | -128.50 M | -108.33 M | -172.20 M | -176.23 M | -191.37 M |
| Pretax Income | -131.01 M | -122.11 M | -108.10 M | -162.25 M | -171.90 M | -202.65 M |
| Tax Provision | -1.00 K | -4.60 M | 20.00 K | 3.00 K | 0.00 | -158.00 K |
| Net Income | -131.00 M | -117.50 M | -108.12 M | -162.25 M | -171.90 M | -202.49 M |
| EPS (Basic) | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 |
| EPS (Diluted) | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 |
| Shares Outstanding | 532.46 M | 529.30 M | 526.72 M | 446.99 M | 417.36 M | 402.77 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.